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Apoptosis is the main mechanism that regulates cell life
span and the elimination of damaged or infected nucleated
cells. Although platelets are enucleate cells, they express at
least part of the apoptotic machinery known from nucleated
cells. In addition, they have been observed to undergo
apoptotic-like events. This has been demonstrated by the
activation and translocation of Bcl-2 family members,
cytochrome c release, activation of caspase-9 and of
caspase-3 [1–10]. These observations indicate that platelets
contain the essential components needed to undergo
programmed cell death executed in the cytoplasm. Recent-
ly, in a murine model of ITP, it has been shown that
apoptotic-like processes can be induced by anti-platelet
antibodies: injection of anti-GPIIb antibodies caused
apoptotic-like events as well as profound thrombocytopenia
[7, 11–14].In this murine ITP model, IVIg treatment was
able to decrease the apoptotic-like events and to improve
the low platelet count [7, 11–13].
As no such study has been performed in paediatric ITP
so far, we started to investigate whether in children with
primary ITP, an enhanced expression of markers of
apoptotic processes can be found. Furthermore, we are
interested to see if such markers correlate to platelet count
and most important to clinical symptoms and if they
decrease after IVIg treatment.
So far, we have shown in a limited number of patients
that caspase-3 is activated in 40% of the platelets in patients
with primary ITP and decreases to 10% after IVIg treatment
([15], manuscript in preparation). In parallel to caspase-3
activation also bleeding signs decreased after IVIg therapy.
In ongoing studies, we investigate caspase-3, caspase-9,
caspase-8, PS-exposure and mitochondrial membrane po-
tential by flow cytometry and caspases by Western blot. We
further will develop an immuno-fluorescence microscopy
protocol for the detection and quantification of activated
caspases in bone marrow smears. Investigating and com-
paring levels of activated caspases and other signs of
apoptosis in platelets and bone marrow samples is
important to understand the initiation of apoptotic pro-
cesses in platelets, whether apoptosis is already triggered in
bone marrow or only in platelets in ITP patients. Further-
more, it is important to understand whether apoptosis
might contribute to the destruction of platelets in ITP
patients.
To increase patient numbers, we invite other clinicians or
laboratories treating respectively investigating ITP to
collaborate with us.
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